BibTex RIS Kaynak Göster

Effect Of Metformın Therapy On Antı Mullerian Hormone Levels In Patıents Wıth Polycystıc Ovary Syndrome

Yıl 2015, Cilt: 4 Sayı: 1, 15 - 19, 01.01.2015

Zeynep Kamalak Ayşe Çarlıoğlu Derya Akdeniz Sema Uysal İlknur İnegöl Gümüş Nilgün Öztürk Turhan

https://doi.org/10.5505/abantmedj.2015.47550

Öz

OBJECTIVE: The polycystic ovary syndrome PCOS is a disorder of reproductive-aged women. The objective of this prospective randomised study was to observe antimullarian hormone AMH levels in patients with PCOS after metformin therapy.METHODS: A total of eighty- four 84 consequtive patients diagnosed according to the criteria proposed in Rotterdam and twenty 28 healthy volunteers were included in the study. Half of patients 42 were treated with 1. 7 gr/ day metformin for six months. The other patients n=42 were observed without therapy for six months and all laboratory tests were compared with control group after 6-month-period.RESULTS: AMH levels were similar in two patient groups before treatment. After metformin therapy, AMH was measured significantly higher in PCOS- untreated group and PCOS+ metformin group before treatment p

Anahtar Kelimeler

Polycystic ovary syndrome metformin anti mullerian hormone

Kaynakça

  • 1. Farah L, Lazenby AJ, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med 1999;44: 870–874.
  • 2. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. J Obstet Gynecol. 1994; 34: 67–72.
  • 3. Balen AH. The pathogenesis of polycystic ovary syndrome: the enigma unravels. Lancet 1999;354: 966- 967
  • 4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18: 774–800
  • 5. Cate, R.L. , Mattaliano, R.J., Hession, C., Tizard, R., Farber, N.M., Cheung, A., Ninfa, E.G., Frey, A.Z., Gash, D.J., Chow, E.P., Fisher, R.A., Bertonis, J.M., Torres, G., Wallner, B.P., Ramachandran, K.L., Ragin, R.C., Manganaro, T.F., MacLaughlin, D.T. & Donahoe, P.K. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45: 685- 698.
  • 6. Teixeria J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr. Rev. 2001;22: 657- 674.
  • 7. Nestler JE, Jakubowicz DJ, Evans WS, Pasguali R. Effects of metformin spontaneous and clomiphene induced ovulation in the polycysticovary syndrome NEJM 1998; 338: 1876.
  • 8. Rajpert-De Meyts, E. , Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 3836- 3844.
  • 9. Renato Pasquali, Alessandra Gambineri et al. Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 2000; 85: 2767- 2774
  • 10. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  • 11. M.E. Fallat, Y. Siow, M. Marra, C. Cook and A. Carrillo, Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis, Fertil Steril 1997; 77: 962–965
  • 12. C.L. Cook, Y. Siow, A.G. Brenner and M.E. Fallat, Relationship between serum mullerianinhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women, Fertil Steril 2002; 77 (1): 141–146
  • 13. Rajpert-De Meyts, E. , Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism.1999; 84: 3836- 3844.
  • 14. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  • 15. P. Pigny, E. Merlen and Y. Robert et al., Elevated serum level of anti- mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest, J Clin Endocrinol Metab 2003 7: 5957–5962
  • 16. de Vet A. Laven JS, deJong FH, Themmen AP;Fauser BC. Antimullerian Hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002 ;77: 357- 62.
  • 17. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Antimullerian hormone serum concentrations in normoovulatory and anovulatory women. J Clin Endocrinol Metab 2004; 89 :318- 23.
  • 18. Christine L. Cook, Yong Siow, Amy G.Brenner. Relationship between serum mullerianinhiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility And Sterility. 2002; 77(1):141- 146.
  • 19. Somunkıran A, Yavuz T, Yücel O, Özdemir İ, Anti- Mullerian Hormone levels during hormonal contraception in women with polycycstic ovary syndrome. European Journal OF Obstetrics & Gynecology and Reproductive Biology 2007; 134: 196- 201.
  • 20. Luque- Ramirez M, Alvarez- Blasco F, Botella- Carretero JI, Martinez- Bermejo E, Lasuncion MA, Escobar- Morreale HF. Comparison of ethinyl- estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92: 2453- 61.
  • 21. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820-6.
  • 22. Falbo A, Rocca M, Russo T, D'Ettore A, Tolino A, Zullo F, Orio F, Palomba S. Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3 (21):16
  • 23. Vicenzo De Leo, Antonio la Marca, Raoul Orvieto and Ginseppe Morgante. Effect of Metformin on Insulin- Like Growth Factor (IGF) 1 and IGF- Binding Protein 1 in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 1985 4: 1598- 1600.
  • 24. Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004; 19(2): 88- 96.
  • 25. A. La Marca, G. Stabile, A.C. Artenisio and A. Volpe, Serum anti-Mullerian hormone throughout the human menstrual cycle, Hum Reprod 2006 21: 3103–7

Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi

Yıl 2015, Cilt: 4 Sayı: 1, 15 - 19, 01.01.2015

Zeynep Kamalak Ayşe Çarlıoğlu Derya Akdeniz Sema Uysal İlknur İnegöl Gümüş Nilgün Öztürk Turhan

https://doi.org/10.5505/abantmedj.2015.47550

Öz

AMAÇ: Polikistik over sendromu, üretken çağdaki kadınlarda sık görülen bir klinik durumdur. Hiperinsülinemi ve insülin direnci, hastalığın patofizyolojisinde önemli bir antite olarak karşımıza çıkar. Çalışmamızın amacı; antimüllerian hormon AMH düzeylerinin metformin tedavisi sonrası değişimini incelemekti.YÖNTEMLER: Rotterdam kriterlerine göre Polikistik over tanısı alan 84 hasta ve 28 sağlıklı gönüllü çalışmaya alındı. Hastaların yarısı n=42 1,7 gr/gün metformin tedavisi alırken diğer 42 hasta tedavisiz izlendi. 6 aylık perioddan sonra hastaların laboratuar testleri karşılaştırıldı.BULGULAR: AMH düzeyleri tedavi öncesi benzerdi. Metformin tedavisi sonrası tedavi alan PCOS hastaları ve kontrol grubu AMH düzeyleri 6 aylık period sonrasında benzer düzeylerde bulundu. Tedavi edilmeyenlere göre 1.7 gr/gün metformin alan hastalarda AMH düzeyleri belirgin düşük olarak izlendi p

Anahtar Kelimeler

Polikistik over sendromu metformin antimüllerian hormon

Kaynakça

  • 1. Farah L, Lazenby AJ, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med 1999;44: 870–874.
  • 2. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. J Obstet Gynecol. 1994; 34: 67–72.
  • 3. Balen AH. The pathogenesis of polycystic ovary syndrome: the enigma unravels. Lancet 1999;354: 966- 967
  • 4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18: 774–800
  • 5. Cate, R.L. , Mattaliano, R.J., Hession, C., Tizard, R., Farber, N.M., Cheung, A., Ninfa, E.G., Frey, A.Z., Gash, D.J., Chow, E.P., Fisher, R.A., Bertonis, J.M., Torres, G., Wallner, B.P., Ramachandran, K.L., Ragin, R.C., Manganaro, T.F., MacLaughlin, D.T. & Donahoe, P.K. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45: 685- 698.
  • 6. Teixeria J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr. Rev. 2001;22: 657- 674.
  • 7. Nestler JE, Jakubowicz DJ, Evans WS, Pasguali R. Effects of metformin spontaneous and clomiphene induced ovulation in the polycysticovary syndrome NEJM 1998; 338: 1876.
  • 8. Rajpert-De Meyts, E. , Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 3836- 3844.
  • 9. Renato Pasquali, Alessandra Gambineri et al. Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 2000; 85: 2767- 2774
  • 10. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  • 11. M.E. Fallat, Y. Siow, M. Marra, C. Cook and A. Carrillo, Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis, Fertil Steril 1997; 77: 962–965
  • 12. C.L. Cook, Y. Siow, A.G. Brenner and M.E. Fallat, Relationship between serum mullerianinhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women, Fertil Steril 2002; 77 (1): 141–146
  • 13. Rajpert-De Meyts, E. , Jorgensen, N., Graem, N., Müller, J., Cate, R.L. & Skakkebaek, N.E. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism.1999; 84: 3836- 3844.
  • 14. Annemarie de Vet, Joop S. E. Laven, Frank H. De Jong. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility And Sterility. 2002;77: 357- 362.
  • 15. P. Pigny, E. Merlen and Y. Robert et al., Elevated serum level of anti- mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest, J Clin Endocrinol Metab 2003 7: 5957–5962
  • 16. de Vet A. Laven JS, deJong FH, Themmen AP;Fauser BC. Antimullerian Hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002 ;77: 357- 62.
  • 17. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Antimullerian hormone serum concentrations in normoovulatory and anovulatory women. J Clin Endocrinol Metab 2004; 89 :318- 23.
  • 18. Christine L. Cook, Yong Siow, Amy G.Brenner. Relationship between serum mullerianinhiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility And Sterility. 2002; 77(1):141- 146.
  • 19. Somunkıran A, Yavuz T, Yücel O, Özdemir İ, Anti- Mullerian Hormone levels during hormonal contraception in women with polycycstic ovary syndrome. European Journal OF Obstetrics & Gynecology and Reproductive Biology 2007; 134: 196- 201.
  • 20. Luque- Ramirez M, Alvarez- Blasco F, Botella- Carretero JI, Martinez- Bermejo E, Lasuncion MA, Escobar- Morreale HF. Comparison of ethinyl- estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92: 2453- 61.
  • 21. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820-6.
  • 22. Falbo A, Rocca M, Russo T, D'Ettore A, Tolino A, Zullo F, Orio F, Palomba S. Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3 (21):16
  • 23. Vicenzo De Leo, Antonio la Marca, Raoul Orvieto and Ginseppe Morgante. Effect of Metformin on Insulin- Like Growth Factor (IGF) 1 and IGF- Binding Protein 1 in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 1985 4: 1598- 1600.
  • 24. Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004; 19(2): 88- 96.
  • 25. A. La Marca, G. Stabile, A.C. Artenisio and A. Volpe, Serum anti-Mullerian hormone throughout the human menstrual cycle, Hum Reprod 2006 21: 3103–7
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Zeynep Kamalak Bu kişi benim

Ayşe Çarlıoğlu Bu kişi benim

Derya Akdeniz Bu kişi benim

Sema Uysal Bu kişi benim

İlknur İnegöl Gümüş Bu kişi benim

Nilgün Öztürk Turhan Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 4 Sayı: 1

Kaynak Göster

APA Kamalak, Z., Çarlıoğlu, A., Akdeniz, D., Uysal, S., vd. (2015). Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi. Abant Medical Journal, 4(1), 15-19. https://doi.org/10.5505/abantmedj.2015.47550
AMA Kamalak Z, Çarlıoğlu A, Akdeniz D, Uysal S, Gümüş İİ, Turhan NÖ. Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi. Abant Med J. Ocak 2015;4(1):15-19. doi:10.5505/abantmedj.2015.47550
Chicago Kamalak, Zeynep, Ayşe Çarlıoğlu, Derya Akdeniz, Sema Uysal, İlknur İnegöl Gümüş, ve Nilgün Öztürk Turhan. “Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi”. Abant Medical Journal 4, sy. 1 (Ocak 2015): 15-19. https://doi.org/10.5505/abantmedj.2015.47550.
EndNote Kamalak Z, Çarlıoğlu A, Akdeniz D, Uysal S, Gümüş İİ, Turhan NÖ (01 Ocak 2015) Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi. Abant Medical Journal 4 1 15–19.
IEEE Z. Kamalak, A. Çarlıoğlu, D. Akdeniz, S. Uysal, İ. İ. Gümüş, ve N. Ö. Turhan, “Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi”, Abant Med J, c. 4, sy. 1, ss. 15–19, 2015, doi: 10.5505/abantmedj.2015.47550.
ISNAD Kamalak, Zeynep vd. “Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi”. Abant Medical Journal 4/1 (Ocak 2015), 15-19. https://doi.org/10.5505/abantmedj.2015.47550.
JAMA Kamalak Z, Çarlıoğlu A, Akdeniz D, Uysal S, Gümüş İİ, Turhan NÖ. Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi. Abant Med J. 2015;4:15–19.
MLA Kamalak, Zeynep vd. “Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi”. Abant Medical Journal, c. 4, sy. 1, 2015, ss. 15-19, doi:10.5505/abantmedj.2015.47550.
Vancouver Kamalak Z, Çarlıoğlu A, Akdeniz D, Uysal S, Gümüş İİ, Turhan NÖ. Polikistik Overli Hastalarda Metformin Tedavisinin Antimüllerian Hormon Düzeylerine Etkisi. Abant Med J. 2015;4(1):15-9.